Cancer clinical trials in the region Auvergne-Rhône-Alpes

316 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Phase 3 Rectal cancer #NCT06402864 #2023-506885-30-00

[TRESOR] Curiethérapie aux rayons X pour la préservation rectale dans l'adénocarcinome rectal intermédiaire bas ou moyen

Adenocarcinoma Localized Locally Advanced None Systemic Treatment-Naive Systemic Treatment-Naive

CHU Saint-Étienne (Saint-Priest-en-Jarez), Centre de Radiothérapie Charcot (Sainte-Foy-lès-Lyon), Centre Léon Bérard (Lyon), Orlam (Villeurbanne), Clinique de la Sauvegarde - Ramsay Santé (Lyon)

Gustave Roussy, Campus du cancer, Grand Paris

Phase 3 Stomach and esophageal cancer #NCT06356311

[TroFuse-015] Étude sur le SACITUZUMAB TIRUMOTECAN dans le traitement de l'adénocarcinome gastro-œsophagien avancé/métastatique

Stomach Oesogastric junction Esophagus Adenocarcinoma Locally Advanced Metastatic 2 3 or more Immunotherapy Chemotherapy

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Merck Sharp & Dohme LLC

Phase 3 Lung cancer #NCT05215340 #2023-507933-12-00

[TROPION-LUNG08] Dato-DXd + PEMBROLIZUMAB vs PEMBROLIZUMAB seul chez des patients atteints d’un cancer du poumon non à petites cellules avancé ou métastatique en première intention

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic PDL1 Positive (>= 50%) None Systemic Treatment-Naive

ALK BRAF EGFR MET NTRK-1/2/3 RET ROS-1 Immunotherapy Targeted therapy Antibody Drug Conjugates (ADC) Immunotherapy Chemotherapy Targeted therapy Antibody Drug Conjugates (ADC)

Centre Léon Bérard (Lyon)

Daiichi Sankyo

Phase 3 Lung cancer #NCT05899608 #2024-513087-26-00

[HARMONi-3] Étude clinique de l'IVONESCIMAB pour le traitement de première intention des patients atteints d'un CPNPC épidermoïde métastatique

NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Non-squamous NSCLC Metastatic None Systemic Treatment-Naive

Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite)

Summit Therapeutics

Phase 3 Lung cancer #NCT04613596 #2023-508922-83-00

[KRYSTAL-7] Essai sur l'ADAGRASIB en association chez des patients présentant une mutation KRAS G12C

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic KRAS G12C PDL1 Positive (>= 50%) None Systemic Treatment-Naive

Centre Hospitalier Universitaire de Grenoble (La Tronche)

Mirati Thérapeutique Inc.

Phase 3 Lung cancer #NCT06117774 #2023-506235-15-00

[DeLLphi-306] Étude évaluant le TARLATAMAB après chimioradiothérapie dans le cancer du poumon à petites cellules de stade limité

SCLC (Small Cell Lung Cancer) Localized None Chemotherapy Radiotherapy

EGFR Bispecific T-cell engager antibodies

Hôpitaux Nord-Ouest - Villefranche-sur-Saône (Gleizé)

Amgen

Phase 3 Lung cancer #NCT06908993 #2024-519971-25-00

TEPOTINIB vs traitement standard chez les patients atteints d'un cancer du poumon non à petites cellules avancé avec mutation de l'exon 14 du gène MET et ayant déjà été traités

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic MET 1 2 Immunotherapy Chemotherapy

ALK BRAF EGFR HER2 KRAS non G12C RET ROS-1 Systemic Treatment-Naive Targeted therapy

Centre Hospitalier de Valence (Valence), Centre Léon Bérard (Lyon), Institut de cancérologie - GHM (Grenoble)

Intergroupe Francophone de Cancérologie Thoracique

Phase 3 Stomach and esophageal cancer #NCT06901531 #2024-519773-19-00

[LUCERNA] Étude du ZOLBETUXIMAB associé au PEMBROLIZUMAB et à la chimiothérapie chez les adultes atteints d'un cancer gastrique

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive

HER2 Immunotherapy Chemotherapy

Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Hôpital Privé Jean Mermoz - Ramsay Santé (Lyon)

Astellas Pharma Développement mondial, Inc.

Phase 3 Lymphoma #NCT05947851 #2022-501560-17-01

[BELLWAVE-010] Etude sur le NEMTABRUTINIB plus VENETOCLAX vs VENETOCLAX + RITUXIMAB en deuxième intention chez les patients atteints d'une leucémie lymphoïde chronique ou d'un lymphome lymphocytique en rechute/réfractaire

B cell lymphoma Lymphocytic lymphoma None Treated / Controled 1 2 3 or more

Systemic Treatment-Naive Targeted therapy

Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand)

Merck Sharp & Dohme LLC

Phase 3 CLL & Richter's syndrome #NCT05947851 #2022-501560-17-01

CLL (Chronic Lymphocytic Leukemia) None Treated / Controled 1 2 3 or more

Systemic Treatment-Naive Targeted therapy

Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand)

Merck Sharp & Dohme LLC